IDEAYA Biosciences has partnered with Roche to conduct a clinical trial combining IDE892, a PRMT5 inhibitor, with Roche's RG6505, a pan-RAS inhibitor, targeting pancreatic ductal adenocarcinoma (PDAC) patients who have MTAP deletion and RAS mutations. IDEAYA will sponsor the trial while Roche supplies RG6505, with joint oversight from both companies. This collaboration aims to address the high unmet need in PDAC, where up to 40% of tumors show MTAP deletion, potentially improving treatment outcomes for patients lacking targeted options. Future plans include exploring a triple combination therapy involving IDE397, another IDEAYA drug.
At B2Gold Corp's 2026 Annual General and Special Meeting, shareholders voted on key company matters with 63.06% turnout. All ten nominated directors were re-elected with strong support, and resolutions to appoint PricewaterhouseCoopers LLP as auditor...
Jim Rickards highlights a tiny $2 stock holding exclusive rights to a massive $2.7 trillion mineral deposit in the US, containing gold, copper, silver, and critical metals vital for technology and defense. The project has been stalled by environmenta...
Aurion Resources Ltd. shareholders overwhelmingly approved a plan for Agnico Eagle Mines Limited to acquire all outstanding Aurion shares at C$2.60 each. The approval was secured at a special meeting, with over 99% voting in favor. The transaction no...
Anika Therapeutics granted 3,360 restricted stock units (RSUs) to a newly hired non-executive employee on June 1, 2026. This grant was made under the company's 2021 Inducement Plan as a material inducement for accepting employment, in compliance with...
Boralex Inc. has received final approval from the Superior Court of Québec for its arrangement with BIF Thunder Holdings Inc., jointly owned by Brookfield Infrastructure Fund V and Caisse de dépôt et placement du Québec. This approval follows shareho...
